newsfilter
← Latest News
Business Wire·

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

DNDi to share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2's oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease Startup